Avalon GloboCare Closes $3.25M Private Placement
Analysis based on 10 articles · First reported Feb 27, 2026 · Last updated Feb 27, 2026
The private placement by Avalon GloboCare is expected to provide capital for debt repayment and working capital, which could positively impact its financial health. This move may be viewed favorably by investors as it strengthens the company's balance sheet and supports its strategic initiatives in AI and diagnostic products.
Avalon GloboCare Corp. announced the closing of a private placement, raising approximately $3.25 million in gross proceeds through the issuance of 6,372,550 shares of common stock (or pre-funded warrants) and associated Series A-1 and A-2 warrants. The warrants have an exercise price of $0.51 per share and could generate an additional $6.5 million if fully exercised. H.C. Wainwright & Co. served as the exclusive placement agent, with Roth Capital Partners as financial advisor. The net proceeds are earmarked for debt repayment, working capital, and general corporate purposes. The securities were offered to accredited investors under Section 4(a)(2) of the Securities Act of 1933 and Regulation D, and Avalon GloboCare has committed to filing registration statements for their resale.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard